Shares jumped 8.6% in pre-market as BioCryst Pharmaceuticals delivered a quarter that topped Wall Street on every line. Revenue of $218.3 million surged 34% from $163.4 million a year ago, beating analyst expectations of $183.3 million by 19%.

Net income hit $78.4 million, or $0.30 per diluted share — a dramatic reversal from a year ago. But the headline number requires dissection: a single deal did a lot of the heavy lifting.

  • A Licensing Deal Padded the Quarter's Numbers

BioCryst recognized $55.7 million in revenue from its European licensing agreement for navenibart, an experimental drug it acquired through the Astria Therapeutics buyout.

The full deal with Neopharmed Gentili includes $70 million upfront, up to $275 million in milestone payments, and royalties of 18%–30% on European sales. Strip out that one-time income, and the beat narrows considerably — a nuance the market may be glossing over.

  • The Core Drug Business Is Still Growing, Just Slowly

ORLADEYO, BioCryst's only marketed blockbuster drug for hereditary angioedema (a rare swelling disorder), brought in $158.2 million — up 10% year-over-year on a comparable basis after backing out European revenue the company divested last year. Steady, but hardly explosive. A newly launched pediatric version has drawn 47 prescriptions before shipping even began , a promising early sign that could widen the addressable patient pool.

  • The Raised Outlook Still Leans on Deal Revenue

Management now targets $690–$715 million in total 2026 revenue, while maintaining ORLADEYO-specific guidance of $625–$645 million. The gap between those two ranges — roughly $65–$70 million — is almost entirely explained by the licensing deal. In other words, the "raise" reflects money already booked, not faster organic growth.

  • Heavy Debt and a Pivotal Data Readout Loom Large

BioCryst ended June with $354 million in cash and investments, but carries a $395 million term loan and $427 million in royalty financing obligations, leaving a stockholders' deficit of $454 million.

Navenibart's pivotal trial results — expected in Q3 2027 — will determine whether BioCryst has a second major drug or an expensive acquisition that doesn't pay off. Until then, the stock trades on faith as much as fundamentals.